OBJECTIVES: The enactment of the Inflation Reduction Act (IRA) in 2022 empowers Medicare (CMS) to negotiate directly with pharmaceutical companies for high-expenditure, sole-source medications lacking generic or biosimilar alternatives. Non-compliance with the IRA’s stringent data collection mandates can lead to significant penalties, including civil fines and a substantial excise tax (65%-95% of US sales).

METHODS: We meticulously analyzed IRA guidelines and processes, focusing on the specifics of data collection (including elements and sources), submission procedures (utilizing designated portals and templates), audit details (timing and particularities), implications of noncompliance, confidentiality issues, and associated costs of compliance.

RESULTS: Manufacturers of selected drugs are required to electronically submit comprehensive data to CMS in standardized formats, encompassing: 1. Research and development (R&D) expenditures; 2. Unit production and distribution costs; 3. Budget impact analyses; 4. Comparative clinical effectiveness (including real-world evidence) and therapeutic value assessments, both general and specific to Medicare subgroups. Internal data (points 1-3) undergo independent audit verification, whereas clinical data (point 4) derive from manufacturer-conducted studies. The Department of Health and Human Services (HHS) will verify data for accuracy, completeness (for 1-3), and relevance (for 4), reserving the right to request supplemental details. Public disclosure will include R&D costs (detailed by phase and funding source); unit costs (broken down by region and dosage form/strength); list prices; and clinical effectiveness data. However, cost-effectiveness and budget impact data will remain confidential. Estimated compliance costs per drug are approximately $100,000 for R&D, $50,000 for production/distribution, and $35,000-$500,000 for clinical data. One estimate suggests price reporting requirements for the US market alone may cost ~$5 million per manufacturer.

CONCLUSIONS: In light of these intricate data requirements and the substantial cost of compliance, proactive strategic planning is crucial for manufacturers, starting as early as the potential selection phase, to ensure full and efficient compliance.